Phase II study of BAY 43-9006 in patients with metastatic thyroid carcinoma.
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Jan 2014 Actual end date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 03 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.